“…1c) 1,5,11,12,20,27,32,34,41,53,56–58,70,71,79,80,83,84,88,90,109,110,113,124,130,133,144,159,160. This overview therefore focuses on the causes of the therapeutic recalcitrance and presents several experimental engineering approaches, including (1) alterations in local hemodynamics, (2) concomitant laser treatment and dermo-vascular imaging, and (3) site-specific pharmaco-laser therapy, with which the therapeutic efficacy of recalcitrant PWSs may be improved.…”